EMERYVILLE, Calif., May 16, 2024 (GLOBE NEWSWIRE) -- Totus Medicines, a company revolutionizing small molecule drug discovery and development using covalent DNA-encoded libraries and AI tools,...
EMERYVILLE, Calif., Jan. 2, 2024 /PRNewswire/ -- Totus Medicines, a company revolutionizing small molecule drug discovery and development through the use of covalent libraries and AI tools, announced today today announced that Totus President and CEO, Nassim Usman, Ph.D., will be presenting a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Wednesday, January 10, 2024, at 2:30 PM PST / 5:30 PM EST.
Small molecule biotech Totus Medicines has closed a $66 million Series B to carry its PI3K? inhibitor through Phase Ia and has named Nassim Usman as its new president and CEO.
EMERYVILLE, Calif., Oct. 19, 2023 /PRNewswire/ -- Totus Medicines, the drug discovery and development company revolutionizing small molecule drugs to end the era of untreatable disease, is pleased to announce the appointment of John Maraganore, Ph.D., to the company's Scientific Advisory Board (SAB). Maraganore brings over three decades of experience and most recently served as the founding CEO and director of Alnylam Pharmaceuticals. He also currently serves as Chair Emeritus of the Biotechnology Innovation Organization (BIO).
EMERYVILLE, Calif., Sept. 27, 2023 /PRNewswire/ -- Totus Medicines, the drug discovery and development company revolutionizing small molecule drugs to end the era of untreatable disease, today announced its participation at this year's Future of R&D Week in Boston from October 3-5. Totus Co-founder, CEO, and CSO Neil Dhawan is serving as the Event Chairperson for the first day of the conference, Next-Generation Undruggable and participating throughout the event.
EMERYVILLE, Calif. , April 13, 2023 /PRNewswire/ -- Totus Medicines, the drug discovery and development company committed to ending the era of untreatable disease, announced today the dosing of the first patient in a Phase 1 clinical trial of TOS-358, the company's first-in-class covalent PI3K? inhibitor for the treatment of numerous cancers with known PIK3CA mutations.
EMERYVILLE, Calif., April 12, 2023 /PRNewswire/ -- Totus Medicines, the drug discovery and development company committed to ending the era of untreatable disease, announced today the appointment of Dr.Lewis Cantley, Dr. Hope Rugo, and Josep Tabernero to the company's Scientific Advisory Board (SAB). Totus has created the first biosearch technology that scans, maps, and decodes effective new drugs thousands of times faster than traditional drug discovery processes. To start, Totus has focused on oncology with an early breakthrough for the most mutated oncogene in cancer, PI3K?, using the Totus Accel™ Platform.
EMERYVILLE, Calif., April 10, 2023 /PRNewswire/ -- Totus Medicines, a clinical stage biotechnology company fueled by its breakthrough Accel™ platform, announced it will be presenting four posters at the American Association for Cancer Research (AACR) Annual Meeting, regarding its lead program, TOS-358, the first highly specific, covalent PI3K? inhibitor. Totus has created the Accel™ Platform that, for the first time ever, can search, map, and decode billions of drug molecules across multiple cellular targets in a single experiment. This has allowed Totus to identify candidate molecules in months, not years, and rapidly advance these molecules toward the clinic. Notably, the Accel™ Platform enabled discovery of TOS-358 at an unprecedented pace. TOS-358 was discovered in under 4 months and received IND approval in ~2 years from original screening. nnTOS-358 represents the first highly specific covalent inhibitor of PI3K?, which is mutated in ~15% of all cancers (Breast, Colorectal, Lung, Bladder, etc.). However, the therapeutic benefit of current molecules is limited by two key problems. Firstly, current non-covalent PI3K? inhibitors cannot achieve continuous >95% target pathway inhibition, which is required for anti-tumor efficacy. Secondly, high doses of current non-covalent PI3K? inhibitors are non-specific and inhibit other PI3K isoforms at effective doses. This leads to toxicity such as hyperglycemia and GI toxicity. TOS-358 represents the first ever highly specific covalent molecule targeting PI3K? that can achieve durable, near 100% inhibition of PI3K? activity and avoid these safety issues in preclinical studies. nnTotus will outline three key points at AACR to support TOS-358 as the best-in-class PI3K? inhibitor:
EMERYVILLE, Calif., Oct. 27, 2022 /PRNewswire/ -- Totus Medicines, a drug discovery company with the mission to make any protein druggable through its breakthrough chemical biology platform, announced yesterday the poster presentation for TOS-358 at the 34th EORTC-NCI-AACR Symposium (ENA 2022) held in Barcelona Oct 26-28, 2022. The poster exhibits data from the clinical development candidate TOS-358, the first highly selective covalent molecule targeting PI3K?, which is the most mutated oncogene in cancer. Totus Medicines is set to start clinical trials of TOS-358 in early 2023.
SAN FRANCISCO, May 5, 2022 /PRNewswire/ -- Totus Medicines, the drug discovery company mapping the universe of molecular drug interactions across the entire human genome to eliminate untreatable diseases, today announced the selection of global pharma leader Tom Hughes, Ph.D., as the chair of the company's board of directors, and revealed the appointment of four members to the company's innovative Scientific Advisory Board (SAB).